Saturday, 31 October 2026European Markets

Coca-ColaEuropacif And SPADEL Have A High Dividend Yield And Return On Equity In The Beverages - Non-Alcoholic Industry.

Loading stream...

(VIANEWS) - Coca-ColaEuropacif (CCEP.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Beverages - Non-Alcoholic industry.

Financial Asset Price Forward Dividend Yield Return on Equity
Coca-ColaEuropacif (CCEP.AS) €55.50 3.15% 21.88%
SPADEL (SPA.BR) €159.00 0.91% 8.58%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. Coca-ColaEuropacif (CCEP.AS)

3.15% Forward Dividend Yield and 21.88% Return On Equity

Coca-Cola Europacific Partners PLC, together with its subsidiaries, produces, distributes, and sells a range of non-alcoholic ready to drink beverages. It offers flavours, mixers, and energy drinks; soft drinks, waters, enhanced water, and isotonic drinks; and ready-to-drink tea and coffee, juices, and other drinks. The company provides its products under the Coca-Cola, Diet Coke, Coca-Cola Zero Sugar, Fanta, Sprite, Monster Energy, Coca-Cola Energy, Relentless, nalu, URGE, BURN, Kuli, REIGN, POWERADE, Appletiser, Schweppes, FINLEY, mezzo mix, Royal Bliss, Lift, Vio SCHORLE, Coca-Cola Signature Mixers, NORDIC MIST, smartwater, Chaudfontaine, AQUARIUS, VILAS del Turbon, BONAQUA, Apollinaris, Krystal, Honest, Costa Coffee, Fuzetea, CHAQWA, NESTEA, Capri-Sun, Oasis, Minute Maid, MER, and Tropico brands. In addition, it engages in the bottling and other operations. The company was formerly known as Coca-Cola European Partners plc and changed its name to Coca-Cola Europacific Partners PLC in May 2021. Coca-Cola Europacific Partners PLC was founded in 1904 and is based in Uxbridge, the United Kingdom.

Earnings Per Share

As for profitability, Coca-ColaEuropacif has a trailing twelve months EPS of €3.69.

PE Ratio

Coca-ColaEuropacif has a trailing twelve months price to earnings ratio of 15.04. Meaning, the purchaser of the share is investing €15.04 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.88%.

Yearly Top and Bottom Value

Coca-ColaEuropacif's stock is valued at €55.50 at 17:40 EST, below its 52-week high of €61.60 and way higher than its 52-week low of €45.00.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 11, 2023, the estimated forward annual dividend rate is 1.79 and the estimated forward annual dividend yield is 3.15%.

More news about Coca-ColaEuropacif.

2. SPADEL (SPA.BR)

0.91% Forward Dividend Yield and 8.58% Return On Equity

Spadel SA produces and markets natural mineral water in Belgium. It offers natural mineral water under the Spa, Bru, Wattwiller, Carola, and Devin brand names. The company is based in Woluwe-Saint-Lambert, Belgium. Spadel SA operates as a subsidiary of Finances Et Industries SA.

Earnings Per Share

As for profitability, SPADEL has a trailing twelve months EPS of €4.15.

PE Ratio

SPADEL has a trailing twelve months price to earnings ratio of 38.31. Meaning, the purchaser of the share is investing €38.31 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.58%.

More news about SPADEL.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com